Boston Scientific Q3 EPS Beats Estimates by 5.6%, Revenues Top Forecasts
Boston Scientific reported Q3 2025 adjusted EPS of $0.75, beating estimates by 5.6%, and revenues of $5.07 billion, up 1.9% above forecasts. The company’s estimated long-term earnings growth rate of 16.4% outpaces the industry’s 13.1%, highlighting robust growth potential.
1. Q3 2025 Earnings Beat Expectations
Boston Scientific delivered adjusted EPS of $0.75 in Q3 2025, surpassing consensus by 5.6%, while revenue reached $5.07 billion, 1.9% above estimates. The stronger margins and top-line performance reflect operational efficiency and solid demand across its core medical device segments.
2. Growth Outlook
Management forecasts long-term earnings growth at 16.4%, outpacing the medical devices industry’s 13.1% average, suggesting robust expansion potential. Investors will monitor segment contributions and product launches to gauge sustainability of above-market growth.